{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"SpaceFlightMission": [], "CitationSubset": ["IM"], "OtherAbstract": [], "KeywordList": [], "GeneralNote": [], "OtherID": [], "InvestigatorList": [], "PMID": "30804001", "DateCompleted": {"Year": "2019", "Month": "12", "Day": "20"}, "DateRevised": {"Year": "2019", "Month": "12", "Day": "20"}, "Article": {"ArticleDate": [{"Year": "2019", "Month": "02", "Day": "25"}], "Language": ["eng"], "ELocationID": ["10.1124/jpet.118.252551"], "Journal": {"ISSN": "1521-0103", "JournalIssue": {"Volume": "369", "Issue": "2", "PubDate": {"Year": "2019", "Month": "May"}}, "Title": "The Journal of pharmacology and experimental therapeutics", "ISOAbbreviation": "J Pharmacol Exp Ther"}, "ArticleTitle": "Characterizing Pharmacokinetic-Pharmacodynamic Relationships and Efficacy of PI3K<i>\u03b4</i> Inhibitors in Respiratory Models of TH2 and TH1 Inflammation.", "Pagination": {"StartPage": "223", "EndPage": "233", "MedlinePgn": "223-233"}, "Abstract": {"AbstractText": ["We leveraged a clinical pharmacokinetic (PK)/pharmacodynamics (PD)/efficacy relationship established with an oral phosphatidylinositol 3-kinase (PI3K)<i>\u03b4</i> inhibitor (Idelalisib) in a nasal allergen challenge study to determine whether a comparable PK/PD/efficacy relationship with PI3K<i>\u03b4</i> inhibitors was observed in preclinical respiratory models of type 2 T helper cell (TH2) and type 1 T helper cell (TH1) inflammation. Results from an in vitro rat blood basophil (CD63) activation assay were used as a PD biomarker. IC<sub>50</sub> values for PI3K<i>\u03b4</i> inhibitors, MSD-496486311, MSD-126796721, Idelalisib, and Duvelisib, were 1.2, 4.8, 0.8, and 0.5 <i>\u03bc</i>M. In the ovalbumin Brown Norway TH2 pulmonary inflammation model, all PI3K<i>\u03b4</i> inhibitors produced a dose-dependent inhibition of bronchoalveolar lavage eosinophils (maximum effect between 80% and 99%). In a follow-up experiment designed to investigate PK attributes [maximum (or peak) plasma concentration (Cmax), area under the curve (AUC), time on target (ToT)] that govern PI3K<i>\u03b4</i> efficacy, MSD-496486311 [3 mg/kg every day (QD) and 100 mg/kg QD] produced 16% and 93% inhibition of eosinophils, whereas doses (20 mg/kg QD, 10 mg/kg twice per day, and 3 mg/kg three times per day) produced 54% to 66% inhibition. Our profiling suggests that impact of PI3K<i>\u03b4</i> inhibitors on eosinophils is supported by a PK target with a ToT over the course of treatment close to the PD IC<sub>50</sub> rather than strictly driven by AUC, Cmax, or Cmin (minimum blood plasma concentration) coverage. Additional studies in an <i>Altenaria alternata</i> rat model, a sheep Ascaris-sensitive sheep model, and a TH1-driven rat ozone exposure model did not challenge our hypothesis, suggesting that an IC<sub>50</sub> level of TE (target engagement) sustained for 24 hours is required to produce efficacy in these traditional models. We conclude that the PK/PD observations in our animal models appear to align with clinical results associated with a TH2 airway disease."], "CopyrightInformation": "Copyright \u00a9 2019 The Author(s)."}, "AuthorList": [{"AffiliationInfo": [{"Identifier": [], "Affiliation": "Merck & Co., Boston, Massachusetts; Merck & Co., Rahway, New Jersey robbie.mcleod@merck.com."}], "Identifier": [], "LastName": "McLeod", "ForeName": "Robbie L", "Initials": "RL"}, {"AffiliationInfo": [{"Identifier": [], "Affiliation": "Merck & Co., Boston, Massachusetts; Merck & Co., Rahway, New Jersey."}], "Identifier": [], "LastName": "Gil", "ForeName": "Malgorzata A", "Initials": "MA"}, {"AffiliationInfo": [{"Identifier": [], "Affiliation": "Merck & Co., Boston, Massachusetts; Merck & Co., Rahway, New Jersey."}], "Identifier": [], "LastName": "Chen", "ForeName": "Dapeng", "Initials": "D"}, {"AffiliationInfo": [{"Identifier": [], "Affiliation": "Merck & Co., Boston, Massachusetts; Merck & Co., Rahway, New Jersey."}], "Identifier": [], "LastName": "Cabal", "ForeName": "Antonio", "Initials": "A"}, {"AffiliationInfo": [{"Identifier": [], "Affiliation": "Merck & Co., Boston, Massachusetts; Merck & Co., Rahway, New Jersey."}], "Identifier": [], "LastName": "Katz", "ForeName": "Jason", "Initials": "J"}, {"AffiliationInfo": [{"Identifier": [], "Affiliation": "Merck & Co., Boston, Massachusetts; Merck & Co., Rahway, New Jersey."}], "Identifier": [], "LastName": "Methot", "ForeName": "Joey", "Initials": "J"}, {"AffiliationInfo": [{"Identifier": [], "Affiliation": "Merck & Co., Boston, Massachusetts; Merck & Co., Rahway, New Jersey."}], "Identifier": [], "LastName": "Woodhouse", "ForeName": "Janice D", "Initials": "JD"}, {"AffiliationInfo": [{"Identifier": [], "Affiliation": "Merck & Co., Boston, Massachusetts; Merck & Co., Rahway, New Jersey."}], "Identifier": [], "LastName": "Dorosh", "ForeName": "Lauren", "Initials": "L"}, {"AffiliationInfo": [{"Identifier": [], "Affiliation": "Merck & Co., Boston, Massachusetts; Merck & Co., Rahway, New Jersey."}], "Identifier": [], "LastName": "Geda", "ForeName": "Prasanthi", "Initials": "P"}, {"AffiliationInfo": [{"Identifier": [], "Affiliation": "Merck & Co., Boston, Massachusetts; Merck & Co., Rahway, New Jersey."}], "Identifier": [], "LastName": "Mehta", "ForeName": "Khamir", "Initials": "K"}, {"AffiliationInfo": [{"Identifier": [], "Affiliation": "Merck & Co., Boston, Massachusetts; Merck & Co., Rahway, New Jersey."}], "Identifier": [], "LastName": "Cicmil", "ForeName": "Milenko", "Initials": "M"}, {"AffiliationInfo": [{"Identifier": [], "Affiliation": "Merck & Co., Boston, Massachusetts; Merck & Co., Rahway, New Jersey."}], "Identifier": [], "LastName": "Baltus", "ForeName": "Gretchen A", "Initials": "GA"}, {"AffiliationInfo": [{"Identifier": [], "Affiliation": "Merck & Co., Boston, Massachusetts; Merck & Co., Rahway, New Jersey."}], "Identifier": [], "LastName": "Bass", "ForeName": "Alan", "Initials": "A"}, {"AffiliationInfo": [{"Identifier": [], "Affiliation": "Merck & Co., Boston, Massachusetts; Merck & Co., Rahway, New Jersey."}], "Identifier": [], "LastName": "Houshyar", "ForeName": "Hani", "Initials": "H"}, {"AffiliationInfo": [{"Identifier": [], "Affiliation": "Merck & Co., Boston, Massachusetts; Merck & Co., Rahway, New Jersey."}], "Identifier": [], "LastName": "Caniga", "ForeName": "Michael", "Initials": "M"}, {"AffiliationInfo": [{"Identifier": [], "Affiliation": "Merck & Co., Boston, Massachusetts; Merck & Co., Rahway, New Jersey."}], "Identifier": [], "LastName": "Yu", "ForeName": "Hongshi", "Initials": "H"}, {"AffiliationInfo": [{"Identifier": [], "Affiliation": "Merck & Co., Boston, Massachusetts; Merck & Co., Rahway, New Jersey."}], "Identifier": [], "LastName": "Gervais", "ForeName": "Francois", "Initials": "F"}, {"AffiliationInfo": [{"Identifier": [], "Affiliation": "Merck & Co., Boston, Massachusetts; Merck & Co., Rahway, New Jersey."}], "Identifier": [], "LastName": "Alves", "ForeName": "Stephen", "Initials": "S"}, {"AffiliationInfo": [{"Identifier": [], "Affiliation": "Merck & Co., Boston, Massachusetts; Merck & Co., Rahway, New Jersey."}], "Identifier": [], "LastName": "Shah", "ForeName": "Sanjiv", "Initials": "S"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "J Pharmacol Exp Ther", "NlmUniqueID": "0376362", "ISSNLinking": "0022-3565"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Phosphoinositide-3 Kinase Inhibitors"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": [], "DescriptorName": "Disease Models, Animal"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["drug therapy", "immunology", "metabolism"], "DescriptorName": "Inflammation"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": ["metabolism"], "DescriptorName": "Phosphatidylinositol 3-Kinases"}, {"QualifierName": ["pharmacokinetics", "pharmacology", "therapeutic use"], "DescriptorName": "Phosphoinositide-3 Kinase Inhibitors"}, {"QualifierName": [], "DescriptorName": "Rats"}, {"QualifierName": ["drug therapy", "immunology", "metabolism"], "DescriptorName": "Respiratory Tract Diseases"}, {"QualifierName": ["drug effects"], "DescriptorName": "Th1 Cells"}, {"QualifierName": ["drug effects"], "DescriptorName": "Th2 Cells"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "2018", "Month": "7", "Day": "30"}, {"Year": "2019", "Month": "2", "Day": "21"}, {"Year": "2019", "Month": "2", "Day": "26", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "12", "Day": "21", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "2", "Day": "27", "Hour": "6", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["30804001", "10.1124/jpet.118.252551", "jpet.118.252551"]}}]}